Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

APLM

Apollomics Inc

Feb 13 • 04:00PM ET

19.79

+0.59 3.07 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN AMGN VRTX BIIB INCY BMRN NBIX EXEL BLUE

| Held by: CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-28.28	Insider Own	99.42%	Shs Outstand	0.11M	Perf Week	2.81%
Market Cap	21.84M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	-	Perf Month	-0.15%
Enterprise Value	20.49M	PEG	-	EPS next Q	-	Inst Own	0.40%	Short Float	-	Perf Quarter	19.79%
Income	-31.19M	P/S	2.57	EPS this Y	-	Inst Trans	-0.10%	Short Ratio	0.71	Perf Half Y	234.86%
Sales	8.50M	P/B	4.49	EPS next Y	-	ROA	-136.51%	Short Interest	0.02M	Perf YTD	5.86%
Book/sh	4.41	P/C	10.45	EPS next 5Y	-	ROE	-380.13%	52W High	42.12 -53.02%	Perf Year	176.01%
Cash/sh	1.89	P/FCF	-	EPS past 3/5Y	-31.06% -28.54%	ROIC	-	52W Low	3.66 440.86%	Perf 3Y	-98.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-4.25%	Volatility	7.30% 9.73%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.41	EPS Y/Y TTM	54.41%	Oper. Margin	-304.27%	ATR (14)	1.92	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.39	Sales Y/Y TTM	-	Profit Margin	-366.92%	RSI (14)	52.37	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.97	EPS Q/Q	-1224.24%	SMA20	2.85%	Beta	1.75	Target Price	400.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	5.80%	Rel Volume	0.28	Prev Close	19.20
Employees	13	LT Debt/Eq	-	Earnings	Dec 22 AMC	SMA200	72.09%	Avg Volume	24.87K	Price	19.79
IPO	Nov 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	7,438	Change	3.07%

Dec-22-25 04:05PM	Apollomics Reports First Half 2025 Financial Results (GlobeNewswire) +10.55% -6.81%
Nov-19-25 05:38PM	Apollomics Announces Settlement of Cayman Litigation (GlobeNewswire) -17.51%
Nov-17-25 11:00PM	Apollomics Announces Changes to its Board of Directors and Composition of Committees (GlobeNewswire) -12.59% -14.50%
Oct-15-25 02:36PM	Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation (GlobeNewswire) +5.79%

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in May 2015 and is headquartered in Foster City, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APLM

Apollomics Inc

Upgrade your FINVIZ experience